Suchergebnisse - "Antirheumatic Agents therapeutic use"

Patients’, caregivers and clinicians’ perspectives on education and support about methotrexate: survey to 26 European Countries

Autoren: Matos, Cristiano Livermore, Polly Ortiz-Piña, Mariana et al.

Quelle: Matos, C, Livermore, P, Ortiz-Piña, M, El Aoufy, K, Buerki, K, Ágoston-Szabó, A, Batšinskaja, D, Melicharová, J, Karlsson, M-L, Claes, K, Rodriguez Vargas, A I, Moholt, E, Ludvigsen, A, Martin, U, Erstling, U, Camon, A, Pais, A, Konstantinou, M, Nikoloudaki, M, Makri, S, Silva, B, Paiva, C, Nikiphorou, E, Marques, A & Ferreira, R J O 2025, 'Patients', caregivers and clinicians' perspectives on education and support about methotrexate : survey to 26 European Countries', ARP rheumatology, vol. 4, no. 2, pp. 91-105. https://doi.org/10.63032/FUWK2508

Schlagwörter: Europe, Adult, Male, Caregivers/psychology, Patient Education as Topic, Methotrexate/therapeutic use, Attitude of Health Personnel, Surveys and Questionnaires, Physicians, Humans, Antirheumatic Agents/therapeutic use, Female, Middle Aged

Dateibeschreibung: application/pdf

Zugangs-URL: https://kclpure.kcl.ac.uk/ws/files/343393374/1594_patients_caregivers_and_clinic_file.pdf

Self-sampling of capillary blood for safety monitoring of DMARD therapy in patients with rheumatic disease: a feasibility and method-comparison study: a feasibility and method-comparison study

Autoren: Josefine Bak H. Adelhelm Trine Rennebod Larsen Ulla Jakobsen et al.

Quelle: Scandinavian Journal of Clinical and Laboratory Investigation. 85:108-115

Schlagwörter: Male, Adult, Blood Specimen Collection, feasibility studies, Antirheumatic Agents/therapeutic use, Rheumatic Diseases/drug therapy, Middle Aged, Capillaries, Self Care, Rheumatology, Blood Specimen Collection/methods, Rheumatic Diseases, Antirheumatic Agents, Chemistry techniques, Humans, Feasibility Studies, analytical, capillaries, Female, Drug Monitoring, Drug Monitoring/methods, validation studies, Aged

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39918982
https://portal.findresearcher.sdu.dk/da/publications/e5f6f608-6353-4604-8b8f-e24db57faa4c
https://doi.org/10.1080/00365513.2025.2463087

Considerations for Coronavirus Disease 2019 Vaccination Among B-Cell-Depleted Patients

Autoren: Ammitzbøll, Christian Thomsen, Marianne Kragh Erikstrup, Christian et al.

Quelle: Ammitzbøll, C, Thomsen, M K, Erikstrup, C & Troldborg, A 2025, 'Considerations for Coronavirus Disease 2019 Vaccination Among B-Cell-Depleted Patients', Rheumatic Diseases Clinics of North America, vol. 51, no. 1, pp. 45-59. https://doi.org/10.1016/j.rdc.2024.09.006

Schlagwörter: 0301 basic medicine, B-Lymphocytes, COVID-19 Vaccines, B-cell depletion, COVID-19 vaccination, SARS-CoV-2, COVID-19/prevention & control, Vaccination, COVID-19, Antirheumatic Agents/therapeutic use, B-Lymphocytes/immunology, Rheumatic Diseases/drug therapy, SARS-CoV-2/immunology, Antibodies, Autoimmune Diseases, 03 medical and health sciences, Rheumatic diseases, 0302 clinical medicine, Autoimmune Diseases/immunology, Antirheumatic Agents, Rheumatic Diseases, Rituximab/therapeutic use, Practice Guidelines as Topic, Humans, Rituximab

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39550106
https://pure.au.dk/portal/en/publications/7d878da6-2d0e-433b-8841-3800cf3506a4
http://www.scopus.com/inward/record.url?scp=85206918329&partnerID=8YFLogxK
https://doi.org/10.1016/j.rdc.2024.09.006

Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial: data from a randomised controlled trial

Autoren: Kristina Lend Jon Lampa Leonid Padyukov et al.

Weitere Verfasser: Kristina Lend Jon Lampa Leonid Padyukov et al.

Quelle: Ann Rheum Dis
Lend, K, Lampa, J, Padyukov, L, Hetland, M L, Heiberg, M S, Nordström, D C, Nurmohamed, M T, Rudin, A, Østergaard, M, Haavardsholm, E A, Hørslev-Petersen, K, Uhlig, T, Sokka-Isler, T, Gudbjornsson, B, Grondal, G, Frazzei, G, Christiaans, J, Wolbink, G, Rispens, T, Twisk, J W R & van Vollenhoven, R F 2024, 'Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis : data from a randomised controlled trial', Annals of the Rheumatic Diseases, vol. 83, no. 12. https://doi.org/10.1136/ard-2024-226024
Lend, K, Lampa, J, Padyukov, L, Hetland, M L, Heiberg, M S, Nordström, D C, Nurmohamed, M T, Rudin, A, Østergaard, M, Haavardsholm, E A, Hørslev-Petersen, K, Uhlig, T, Sokka-Isler, T, Gudbjornsson, B, Grondal, G, Frazzei, G, Christiaans, J, Wolbink, G, Rispens, T, Twisk, J W R & van Vollenhoven, R F 2024, ' Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis : data from a randomised controlled trial ', Annals of the Rheumatic Diseases, vol. 83, no. 12, pp. 1657-1665 . https://doi.org/10.1136/ard-2024-226024

Schlagwörter: Male, Adult, Methotrexate/therapeutic use, Humanized/therapeutic use, Epitopes/immunology, Antirheumatic Agents/therapeutic use, Rheumatoid Arthritis, Antibodies, Monoclonal, Humanized, Severity of Illness Index, Antibodies, Anti-Citrullinated Protein Antibodies, Rheumatoid/drug therapy, Arthritis, Rheumatoid, Abatacept, Epitopes, Drug Therapy, Rheumatoid Factor, Rheumatoid, Monoclonal, Humans, HLA-DRB1 Chains/genetics, Alleles, Aged, Arthritis, Middle Aged, Certolizumab Pegol/therapeutic use, Anti-Citrullinated Protein Antibodies/blood, General medicine, internal medicine and other clinical medicine, 3. Good health, Biological Therapy, Rheumatoid Factor/blood, Abatacept/therapeutic use, Treatment Outcome, Methotrexate, Antirheumatic Agents, Combination, Certolizumab Pegol, Female, Drug Therapy, Combination, HLA-DRB1 Chains

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39079894
https://research.vumc.nl/en/publications/29a841b6-7462-40f3-8111-1f7fed354859
http://hdl.handle.net/10138/584533
https://curis.ku.dk/ws/files/413564336/1657.full.pdf
https://portal.findresearcher.sdu.dk/da/publications/af805c06-6862-49fe-8933-b33cfe953cb4
https://doi.org/10.1136/ard-2024-226024

Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set: a meta-epidemiological study on the appropriate use of a core outcome set

Autoren: Philip Rask Lage-Hansen Nikoletta Svendsen Jamie Kirkham et al.

Quelle: Rask Lage-Hansen, P, Svendsen, N, Kirkham, J, Mai Nielsen, S, Amris, K, de Wit, M, Boers, M, Ellingsen, T & Christensen, R 2024, 'Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set', Ann Rheum Dis, vol. 83, no. 10, pp. 1288-1294.

Schlagwörter: Biological Products, Health Care/methods, Outcome Assessment, Endpoint Determination, Arthritis, Antirheumatic Agents/therapeutic use, Patient Reported Outcome, Severity of Illness Index, Rheumatoid/drug therapy, Biological Therapy, Health Care, Arthritis, Rheumatoid, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Rheumatoid, Antirheumatic Agents, Outcome Assessment, Health Care, Humans, Patient Reported Outcome Measures, Molecular Targeted Therapy, Biological Products/therapeutic use, Molecular Targeted Therapy/methods, Randomized Controlled Trials as Topic

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38777377
https://research.manchester.ac.uk/en/publications/3697c5d6-2e48-42a3-833b-2e021c4baaca
https://portal.findresearcher.sdu.dk/da/publications/f4bdf1a7-85f4-4104-9bf6-fa4cc955ff5a
https://doi.org/10.1136/ard-2024-225523

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update: 2023 update

Autoren: Gossec, Laure Kerschbaumer, Andreas Ferreira, Ricardo et al.

Weitere Verfasser: Gossec, Laure Kerschbaumer, Andreas Ferreira, Ricardo et al.

Quelle: Ann Rheum Dis
Scopus
RUO. Repositorio Institucional de la Universidad de Oviedo
Universidad de Oviedo (UNIOVI)
Gossec, L, Kerschbaumer, A, Ferreira, R J O, Aletaha, D, Baraliakos, X, Bertheussen, H, Boehncke, W-H, Esbensen, B A, McInnes, I B, McGonagle, D, Winthrop, K L, Balanescu, A, Balint, P V, Burmester, G R, Cañete, J D, Claudepierre, P, Eder, L, Hetland, M L, Iagnocco, A, Kristensen, L E, Lories, R, Queiro, R, Mauro, D, Marzo-Ortega, H, Mease, P J, Nash, P, Wagenaar, W, Savage, L, Schett, G, Shoop-Worrall, S J W, Tanaka, Y, Van Den Bosch, F E, van der Helm-van Mil, A, Zabotti, A, van der Heijde, D & Smolen, J S 2024, ' EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies : 2023 update ', Annals of the Rheumatic Diseases, vol. 83, no. 6, pp. 706-719 . https://doi.org/10.1136/ard-2024-225531
Shoop-Worrall, S & al, E 2024, 'EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update', Annals of the rheumatic diseases, vol. 83, no. 6. https://doi.org/10.1136/ard-2024-225531
ANNALS OF THE RHEUMATIC DISEASES

Schlagwörter: MULTICENTER, Anti-Inflammatory Agents, biological drug, Clinical sciences, Antirheumatic Agents/therapeutic use, DOUBLE-BLIND, Medicine and Health Sciences, treatment, INDUCTION, Anti-Inflammatory Agents, Non-Steroidal, disease-modifying drug, 3. Good health, 3204 Immunology, Biological Therapy, [SDV] Life Sciences [q-bio], PHASE 3B, 1107 Immunology, Psoriatic arthritis, Antirheumatic Agents, Psoriatic/drug therapy, TRIAL, Biological Products/therapeutic use, Life Sciences & Biomedicine, management, Clinical pharmacology and therapeutics, MAINTENANCE THERAPY, Non-Steroidal/therapeutic use, USTEKINUMAB, Methotrexate/therapeutic use, Immunology, Psoriatic Arthritis, EULAR, BIMEKIZUMAB, Anti-Inflammatory Agents, Non-Steroidal / therapeutic use, UPADACITINIB, Methotrexate / therapeutic use, 1117 Public Health and Health Services, 12. Responsible consumption, Rheumatology, SDG 3 - Good Health and Well-being, Humans, Biosimilar Pharmaceuticals, Arthritis, Psoriatic / drug therapy, Biological Products, Science & Technology, Arthritis, Arthritis, Psoriatic, Antirheumatic Agents / therapeutic use, 3202 Clinical sciences, Biology and Life Sciences, 1103 Clinical Sciences, Treatment, Recommendation, TOFACITINIB, Arthritis & Rheumatology, Methotrexate, recommendations, Biological Products / therapeutic use

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38499325
https://research.manchester.ac.uk/en/publications/e24b887d-792a-4e0c-8fa6-7000a9293274
https://doi.org/10.1136/ard-2024-225531
https://research.tilburguniversity.edu/en/publications/c4d1afba-8022-4b3f-8f3e-ff2d7b538b43
https://doi.org/10.1136/ard-2024-225531
https://hal.science/hal-04564234v1
https://hal.science/hal-04564234v1/document
https://doi.org/10.1136/ard-2024-225531
https://lirias.kuleuven.be/handle/20.500.12942/752738
https://doi.org/10.1136/ard-2024-225531
https://archive-ouverte.unige.ch/unige:183476
https://doi.org/10.1136/ard-2024-225531
https://hdl.handle.net/10651/75050
https://curis.ku.dk/ws/files/391891044/706.full.pdf
https://hdl.handle.net/11591/529350
https://doi.org/10.1136/ard-2024-225531
http://doi.org/10.1136/ard-2024-225531
https://biblio.ugent.be/publication/01HWZCSZ5KAYA0JD699ETSVJ8G
http://hdl.handle.net/1854/LU-01HWZCSZ5KAYA0JD699ETSVJ8G
https://biblio.ugent.be/publication/01HWZCSZ5KAYA0JD699ETSVJ8G/file/01JPAP261HS4YFQC1D0VDQK8CJ
https://hdl.handle.net/2318/1963438
https://doi.org/10.1136/ard-2024-225531

Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the ‘JAK-pot’ study)

Autoren: Aymon, Romain Mongin, Denis Bergstra, Sytske Anne et al.

Weitere Verfasser: Aymon, Romain Mongin, Denis Bergstra, Sytske Anne et al.

Quelle: Ann Rheum Dis
Aymon, R, Mongin, D, Bergstra, S A, Choquette, D, Codreanu, C, De Cock, D, Dreyer, L, Elkayam, O, Huschek, D, Hyrich, K L, Iannone, F, Inanc, N, Kearsley-Fleet, L, Koca, S S, Kvien, T K, Leeb, B F, Lukina, G, Nordström, D C, Pavelka, K, Pombo-Suarez, M, Rodrigues, A, Rotar, Z, Strangfeld, A, Verschueren, P, Westermann, R, Zavada, J, Courvoisier, D S, Finckh, A & Lauper, K 2024, 'Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)', Annals of the Rheumatic Diseases, vol. 83, no. 4, pp. 421-428. https://doi.org/10.1136/ard-2023-224670
Aymon, R, Mongin, D, Bergstra, S A, Choquette, D, Codreanu, C, De Cock, D, Dreyer, L, Elkayam, O, Huschek, D, Hyrich, K L, Iannone, F, Inanc, N, Kearsley-Fleet, L, Koca, S S, Kvien, T K, Leeb, B F, Lukina, G, Nordström, D C, Pavelka, K, Pombo-Suarez, M, Rodrigues, A, Rotar, Z, Strangfeld, A, Verschueren, P, Westermann, R, Zavada, J, Courvoisier, D S, Finckh, A & Lauper, K 2024, 'Evaluation of discontinuation for adverse events of JAK inhibitors and bDMARDs in an international collaboration of rheumatoid arthritis registers (the 'JAK-pot' study)', Annals of the rheumatic diseases, vol. 83, no. 4, pp. 421-428. https://doi.org/10.1136/ard-2023-224670

Schlagwörter: Epidemiology, Antirheumatic Agents/therapeutic use, Rheumatoid Arthritis, 1117 Public Health and Health Services, Arthritis, Rheumatoid, Baricitinib, Rheumatology, Arthritis, Rheumatoid / drug therapy, Tumor Necrosis Factor Inhibitors/therapeutic use, Humans, Janus Kinase Inhibitors, Janus Kinase Inhibitors / therapeutic use, Tumor Necrosis Factor Inhibitors / therapeutic use, Sulfonamides, Science & Technology, Tumor Necrosis Factor-alpha, Janus Kinase Inhibitors/therapeutic use, Antirheumatic Agents / therapeutic use, 3202 Clinical sciences, 1103 Clinical Sciences, azetidines, 16. Peace & justice, General medicine, internal medicine and other clinical medicine, Arthritis & Rheumatology, 3. Good health, Biological Therapy, 3204 Immunology, Treatment Outcome, 1107 Immunology, Arthritis, Rheumatoid/drug therapy, Purines, Antirheumatic Agents, Azetidines, Pyrazoles, Tumor Necrosis Factor Inhibitors, Life Sciences & Biomedicine

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38071508
https://vbn.aau.dk/ws/files/697666659/Aymon_et_al._2024_._Evaluation_of_discontinuation_for_adverse_events_of_JAK_inhibitors_and_bDMARDs_in_an_international_collaboration_of_rheumatoid_arthritis_registers_the_JAK-pot_study_.pdf
https://doi.org/10.1136/ard-2023-224670
https://vbn.aau.dk/da/publications/14203d30-1d31-4796-ab71-7b9446012fc4
http://www.scopus.com/inward/record.url?scp=85187654831&partnerID=8YFLogxK
https://lirias.kuleuven.be/handle/20.500.12942/741405
https://doi.org/10.1136/ard-2023-224670
https://archive-ouverte.unige.ch/unige:178520
https://doi.org/10.1136/ard-2023-224670
http://hdl.handle.net/10138/574261
https://research.manchester.ac.uk/en/publications/acbd935e-196b-4dcb-87f1-70e1561e7eb7
https://doi.org/10.1136/ard-2023-224670
https://biblio.vub.ac.be/vubir/evaluation-of-discontinuation-for-adverse-events-of-jak-inhibitors-and-bdmards-in-an-international-collaboration-of-rheumatoid-arthritis-registers-the-jakpot-study(3199ffd5-40a6-43ff-b564-686c5946a01b).html
https://hdl.handle.net/20.500.14017/3199ffd5-40a6-43ff-b564-686c5946a01b
https://doi.org/10.1136/ard-2023-224670
https://hdl.handle.net/1887/3736621

How can trial designs better serve the needs of children and young people with juvenile idiopathic arthritis?

Autoren: Freya Luling, Feilding Laura, Crosby Emily, Earle et al.

Quelle: The Lancet Rheumatology. 6:e648-e652

Schlagwörter: Clinical Trials as Topic, Adolescent, Research Design, Arthritis, Antirheumatic Agents, Juvenile/drug therapy, Humans, Clinical Trials as Topic/ethics, Antirheumatic Agents/therapeutic use, Child, Arthritis, Juvenile

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38552652

Analysis of the shorter drug survival times for Janus kinase inhibitors and interleukin-17 inhibitors compared with tumor necrosis factor inhibitors in a real-world cohort of axial spondyloarthritis patients - a retrospective analysis from the RHADAR network

Autoren: Patrick-Pascal Strunz Matthias Englbrecht Linus Maximilian Risser et al.

Quelle: Rheumatol Int

Schlagwörter: Male, Adult, 0301 basic medicine, ddc:610, Time Factors, Interleukin-17, Observational Research, Middle Aged, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Antirheumatic Agents, Germany, Humans, Janus Kinase Inhibitors, Female, Tumor Necrosis Factor Inhibitors, Tumor Necrosis Factor Inhibitors/therapeutic use [MeSH], Drug persistence, Female [MeSH], Kaplan-meier analysis, Secukinumab, Adult [MeSH], Humans [MeSH], Interleukin-17/antagonists, Treatment Outcome [MeSH], Ixekizumab, Janus Kinase Inhibitors/therapeutic use [MeSH], Retrospective Studies [MeSH], Middle Aged [MeSH], Tofacitinib, Time Factors [MeSH], Ankylosing spondylitis, Male [MeSH], Antirheumatic Agents/therapeutic use [MeSH], Bechterew ́s disease, Germany [MeSH], Axial Spondyloarthritis/drug therapy [MeSH], Adalimumab, Upadacitinib, Axial Spondyloarthritis, Retrospective Studies

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39136784
https://repository.publisso.de/resource/frl:6500231
https://opus.bibliothek.uni-wuerzburg.de/files/39156/00296_2024_Article_5671.pdf
https://opus.bibliothek.uni-wuerzburg.de/frontdoor/index/index/docId/39156
https://doi.org/10.1007/s00296-024-05671-9
https://nbn-resolving.org/urn:nbn:de:bvb:20-opus-391567

Current treatment in macrophage activation syndrome worldwide: a systematic literature review to inform the METAPHOR project

Autoren: Baldo, Francesco Erkens, Remco G A Mizuta, Mao et al.

Quelle: Rheumatology (Oxford)

Schlagwörter: Cyclosporine / therapeutic use, Mucocutaneous Lymph Node Syndrome, Dexamethasone, Lupus Erythematosus, Systemic / drug therapy, haemophagocytic lymphohistiocytosis, haemophagocytic syndromes, macrophage activation syndrome, treatment, 03 medical and health sciences, 0302 clinical medicine, Pyrimidines / therapeutic use, Nitriles, Humans, Lupus Erythematosus, Systemic, Glucocorticoids, Macrophage Activation Syndrome / drug therapy, Glucocorticoids / therapeutic use, Macrophage Activation Syndrome, Antirheumatic Agents / therapeutic use, Mucocutaneous Lymph Node Syndrome / drug therapy, Pyrazoles / therapeutic use, Dexamethasone / therapeutic use, Arthritis, Juvenile, 3. Good health, Interleukin 1 Receptor Antagonist Protein, Pyrimidines, Haemophagocytic lymphohistiocytosis, Antirheumatic Agents, Systematic Review and Meta Analysis, Cyclosporine, Pyrazoles, Arthritis, Juvenile / drug therapy, Interleukin 1 Receptor Antagonist Protein / therapeutic use

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39058514
https://hdl.handle.net/10281/538781
https://doi.org/10.1093/rheumatology/keae391
https://hdl.handle.net/10807/302636
https://doi.org/10.1093/rheumatology/keae391
https://hdl.handle.net/11573/1741227
https://doi.org/10.1093/rheumatology/keae391
https://urn.nsk.hr/urn:nbn:hr:105:267685
https://doi.org/10.1093/rheumatology/keae391

A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs: Establishing a Framework to Create a 'Safety Checklist'

Autoren: Skaarup, Lykke Ingrid, Elvina Sepriano, Alexandre et al.

Quelle: Skaarup, L, Ingrid, E, Sepriano, A, Nikiphorou, E, Østgård, R, Lauper, K, Grosse-Michaelis, I, Kloppenburg, M, Glintborg, B, Liew, D F L & Kragstrup, T W 2024, 'A Systematic Overview of Contraindications and Special Warnings for Biologic and Targeted Synthetic Disease Modifying Antirheumatic Drugs : Establishing a Framework to Create a "Safety Checklist"', Drug Safety, vol. 47, no. 11, pp. 1075-1093. https://doi.org/10.1007/s40264-024-01461-1

Schlagwörter: Biological Products, United States Food and Drug Administration, Antirheumatic Agents / therapeutic use, Contraindications, Drug, United States, Checklist, 3. Good health, Antirheumatic Agents, Biological Products / adverse effects, Humans, Antirheumatic Agents / adverse effects, Biological Products / therapeutic use, Drug Labeling

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39012469
https://archive-ouverte.unige.ch/unige:185261
https://doi.org/10.1007/s40264-024-01461-1
https://pure.au.dk/portal/en/publications/34489cc0-504f-48b9-8484-bfa29f97c271
http://www.scopus.com/inward/record.url?scp=85198703421&partnerID=8YFLogxK
https://doi.org/10.1007/s40264-024-01461-1

Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer

Autoren: Sebbag, Eden Molina-Collada, Juan Ndoye, Ramatoulaye et al.

Quelle: Sebbag, E, Molina-Collada, J, Ndoye, R, Aletaha, D, Askling, J, Gente, K, Bertheussen, H, Bitoun, S, Bolek, E C, Buch, M H, Burmester, G R, Canhão, H M, Chatzidionysiou, K, Curtis, J R, Danlos, F-X, Guimarães, V, Hetland, M L, Iannone, F, Kostine, M, Kragstrup, T W, Kvien, T K, Regierer, A C, Schulze-Koops, H, Sedmak, N, Silva-Fernández, L, Szekanecz, Z, Lauper, K, Finckh, A & Gottenberg, J-E 2025, 'Systematic literature review and meta-analysis informing the EULAR points to consider on the initiation of targeted therapies in patients with inflammatory arthritis and a history of cancer', Annals of the Rheumatic Diseases, vol. 84, no. 4, ard-2024-225981, pp. 643-652. https://doi.org/10.1136/ard-2024-225981

Schlagwörter: Inflammation, Arthritis, Antirheumatic Agents / therapeutic use, Autoimmunity, Arthritis / drug therapy, Biological Therapy, Neoplasms / chemically induced, Arthritis, Rheumatoid / drug therapy, Arthritis, Rheumatoid / complications, Humans, Antirheumatic Agents / adverse effects, Neoplasms / epidemiology, Molecular Targeted Therapy / adverse effects, Neoplasms / complications

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39739386
https://archive-ouverte.unige.ch/unige:185251
https://doi.org/10.1136/ard-2024-225981
https://ard.bmj.com/content/early/2024/12/20/ard-2024-225981
https://doi.org/10.1136/ard-2024-225981
https://pure.au.dk/portal/en/publications/fe242cbc-d5e7-4f05-b917-bb818ab7c061
http://www.scopus.com/inward/record.url?scp=85216077915&partnerID=8YFLogxK

Durable control of psoriatic arthritis with guselkumab across domains and patient characteristics: post hoc analysis of a phase 3 study

Autoren: Ritchlin, Christopher T Mease, Philip J Boehncke, Wolf-Henning et al.

Quelle: Clin Rheumatol

Schlagwörter: Male, Adult, Guselkumab, Cross-Over Studies, Antibodies, Monoclonal, Humanized / therapeutic use, Arthritis, Psoriatic, Antirheumatic Agents / therapeutic use, Middle Aged, Antibodies, Monoclonal, Humanized, Severity of Illness Index, 03 medical and health sciences, Treatment Outcome, 0302 clinical medicine, Double-Blind Method, Disease control, Psoriatic arthritis, Antirheumatic Agents, Humans, Original Article, Female, Patient Reported Outcome Measures, Domain, Patient-reported outcome, Arthritis, Psoriatic / drug therapy

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38844682
https://archive-ouverte.unige.ch/unige:183413
https://doi.org/10.1007/s10067-024-06991-8

Efficacy and safety of pharmacological treatment of psoriatic arthritis: a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis

Autoren: Kerschbaumer, Andreas Smolen, Josef S Ferreira, Ricardo J O et al.

Weitere Verfasser: Kerschbaumer, Andreas Smolen, Josef S Ferreira, Ricardo J O et al.

Quelle: Ann Rheum Dis
Kerschbaumer, A, Smolen, J S, Ferreira, R J O, Bertheussen, H, Baraliakos, X, Aletaha, D, McGonagle, D G, van der Heijde, D, McInnes, I B, Esbensen, B A, Winthrop, K L, Boehncke, W-H, Schoones, J W & Gossec, L 2024, ' Efficacy and safety of pharmacological treatment of psoriatic arthritis : a systematic literature research informing the 2023 update of the EULAR recommendations for the management of psoriatic arthritis ', Annals of the Rheumatic Diseases, vol. 83, no. 6, pp. 760-774 . https://doi.org/10.1136/ard-2024-225534

Schlagwörter: psoriatic arthritis, Biological Products, DMARDs (biological), Psoriatic Arthritis, Arthritis, Psoriatic, Antirheumatic Agents / therapeutic use, Therapeutics, 3. Good health, [SDV] Life Sciences [q-bio], Biological Therapy, Treatment Outcome, Antirheumatic Agents, recommendations, Practice Guidelines as Topic, Humans, Biological Products / therapeutic use, treatment algorithms, DMARDs (synthetic), psoriatic arthritis DMARDs (biological) DMARDs (synthetic) treatment algorithms recommendations, Arthritis, Psoriatic / drug therapy

Dateibeschreibung: application/pdf

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38503473
https://curis.ku.dk/ws/files/392572925/760.full.pdf
https://hal.science/hal-04977903v1/document
https://doi.org/10.1136/ard-2024-225534
https://hal.science/hal-04977903v1

Novel therapies in juvenile idiopathic arthritis

Autoren: Sage, Anne M Clarke, Sarah L N Ramanan, Athimalaipet V

Quelle: Current Opinion in Rheumatology. 36:328-335

Schlagwörter: Biological Products, Arthritis, Juvenile/drug therapy, Antirheumatic Agents/therapeutic use, Arthritis, Juvenile, 3. Good health, 03 medical and health sciences, 0302 clinical medicine, Antirheumatic Agents, Humans, Biological Products/therapeutic use, Child

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38775143

The RESIST Study: Examining Cognitive Change in Rheumatoid Arthritis Patients with Mild Cognitive Impairment Being Treated with a TNF-Inhibitor Compared to a Conventional Synthetic Disease-Modifying Anti-Rheumatic Drug

Autoren: Marr, Calum McDowell, Bethany Holmes, Clive et al.

Quelle: Journal of Alzheimer’s Disease. 99:161-175

Schlagwörter: rheumatoid arthritis, Male, Neuropsychological Tests, Rheumatoid - drug therapy - complications - psychology, Arthritis, Rheumatoid, 03 medical and health sciences, mild cognitive impairment, 0302 clinical medicine, Humans, Cognitive Dysfunction, Antirheumatic Agents - therapeutic use, tumor necrosis factor-alpha, Aged, Cognitive Dysfunction - drug therapy, Tumor Necrosis Factor-alpha, Arthritis, Middle Aged, Mental Status and Dementia Tests, 3. Good health, inflammation, Tumor Necrosis Factor Inhibitors - therapeutic use, Antirheumatic Agents, Tumor Necrosis Factor-alpha - antagonists & inhibitors, Female, Tumor Necrosis Factor Inhibitors, Alzheimer's disease

Dateibeschreibung: text

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38669538

‘I couldn’t carry on taking a drug like that’: a qualitative study of patient perspectives on side effects from rheumatology drugs: A qualitative study of patient perspectives on side effects from rheumatology drugs

Autoren: Dorthe B Berthelsen Sabrina M Nielsen Marianne U Rasmussen et al.

Quelle: Berthelsen, D B, Nielsen, S M, Rasmussen, M U, Voshaar, M, Richards, P, Bartlett, S J, Hazlewood, G S, Shea, B J, Tugwell, P, Ellingsen, T, Jørgensen, T S, Kristensen, S, Simon, L S, Christensen, R, Flurey, C A & OMERACT Safety Working Group 2025, '"I couldn't carry on taking a drug like that": A qualitative study of patient perspectives on side effects from rheumatology drugs', Rheumatology, vol. 64, no. 3, keae223, pp. 994-1002. https://doi.org/10.1093/rheumatology/keae223

Schlagwörter: Adult, Male, safety, harms, rheumatology, OMERACT, Antirheumatic Agents/therapeutic use, Rheumatic Diseases/drug therapy, Focus Groups, Middle Aged, core outcome set, 16. Peace & justice, adverse events, 3. Good health, Activities of Daily Living, Quality of Life, Humans, Female, Qualitative Research, Aged, Drug-Related Side Effects and Adverse Reactions/psychology

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38613847
https://vbn.aau.dk/da/publications/3419d1d1-31c9-4262-8207-a128863a23b1
https://doi.org/10.1093/rheumatology/keae223
http://www.scopus.com/inward/record.url?scp=86000185988&partnerID=8YFLogxK

Aktuelle Zahlen zur rheumatologischen Versorgung – Jahresbericht aus der Kerndokumentation der regionalen kooperativen Rheumazentren

Autoren: Albrecht, Katinka Thiele, Katja Alexander, Tobias et al.

Quelle: Z Rheumatol

Schlagwörter: Versorgung, Aged, 80 and over [MeSH], Langzeitbeobachtung, Aged [MeSH], Rheumatoide Arthritis, Rheumatology/statistics, Rheumatische Erkrankungen, Rheumatic Diseases/therapy [MeSH], Databases, Factual [MeSH], Male [MeSH], Prevalence [MeSH], Versorgungsforschung, Health care research, Rheumatology, Adolescent [MeSH], Female [MeSH], Long-term observational research, Adult [MeSH], Humans [MeSH], Rheumatoid arthritis, Treatment Outcome [MeSH], Middle Aged [MeSH], Cross-Sectional Studies [MeSH], Arthritis, Rheumatoid/epidemiology [MeSH], Rheumatic Diseases/epidemiology [MeSH], Arthritis, Rheumatoid/therapy [MeSH], Antirheumatic Agents/therapeutic use [MeSH], Germany [MeSH], Young Adult [MeSH], Rheumatologie, Rheumatic diseases

Zugangs-URL: https://repository.publisso.de/resource/frl:6515201

Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis

Autoren: Cagnotto, Giovanni Juhl, Carsten B. Ahlström, Fredrik et al.

Quelle: Cagnotto, G, Juhl, C B, Ahlström, F, Wikström, F, Bruschettini, M, Petersson, I, Dreyer, L & Compagno, M 2025, 'Tumor necrosis factor (TNF) inhibitors for juvenile idiopathic arthritis', Cochrane Database of Systematic Reviews, vol. 2025, no. 2, CD013715. https://doi.org/10.1002/14651858.CD013715.pub2

Schlagwörter: Piperidines/therapeutic use, Adolescent, Methotrexate/therapeutic use, Juvenile/drug therapy, Antirheumatic Agents/therapeutic use, 3-Ring, Antibodies, Monoclonal, Humanized, Azetidines/therapeutic use, Abatacept, Pyrazoles/therapeutic use, Piperidines, Bias, Heterocyclic Compounds, Adalimumab/therapeutic use, Tumor Necrosis Factor Inhibitors/therapeutic use, Purines/therapeutic use, Humans, Arthritis, Juvenile/drug therapy, Child, Placebos/therapeutic use, Randomized Controlled Trials as Topic, Sulfonamides, Tumor Necrosis Factor-alpha/antagonists & inhibitors, Tumor Necrosis Factor-alpha, Arthritis, Pyrimidines/therapeutic use, Sulfonamides/therapeutic use, Arthritis, Juvenile, Methotrexate, Pyrimidines, Purines, Antirheumatic Agents, Quality of Life, Azetidines, Pyrazoles, Tumor Necrosis Factor Inhibitors, Heterocyclic Compounds, 3-Ring

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/39976227

Modelling Treatment Sequences in Immunology: Optimizing Patient Outcomes

Autoren: Rose J. Hart Fareen Hassan Sarah Alulis et al.

Quelle: Adv Ther

Schlagwörter: Arthritis, Rheumatoid, Treatment Outcome, Crohn Disease/drug therapy [MeSH], Italy [MeSH], Response, Sequencing, Humans [MeSH], Rheumatoid arthritis, Non-radiographic axial spondyloarthritis, Treatment Outcome [MeSH], Arthritis, Rheumatoid/drug therapy [MeSH], Psoriasis/drug therapy [MeSH], Psoriatic arthritis, Ankylosing spondylitis, Plaque psoriasis, Colitis, Ulcerative/drug therapy [MeSH], Arthritis, Psoriatic/drug therapy [MeSH], Optimisation, Antirheumatic Agents/therapeutic use [MeSH], Original Research, Crohn's disease, Spondylitis, Ankylosing/drug therapy [MeSH], Ulcerative colitis, Italy, Crohn Disease, Antirheumatic Agents, Arthritis, Psoriatic, Humans, Psoriasis, Spondylitis, Ankylosing, Colitis, Ulcerative

Zugangs-URL: https://pubmed.ncbi.nlm.nih.gov/38554238
https://repository.publisso.de/resource/frl:6497129